Tumor-Targeting Version of Thymosin Alpha-1 Peptide Shows Enhanced Antitumor Activity in Melanoma and Lung Cancer

Researchers designed a fusion protein combining thymosin alpha-1 with the tumor-homing peptide iRGD. They tested it in multiple mouse models (BALB/c, C57BL, ICR, and nude mice) with melanoma and lung cancer tumors. They assessed T-cell activation, CD86 expression, tumor accumulation, tumor vessel density, cell attachment, and immunomodulatory activity in hydrocortisone-induced immunosuppression models. Circular dichroism spectroscopy was used to analyze protein structure.

Thymosin alpha-1 is already used clinically as an immune-boosting peptide, but its effects are broad and non-specific. By fusing it with the tumor-homing peptide iRGD, researchers created a version that specifically targets tumors while retaining its immune-stimulating properties. This targeted approach could make thymosin alpha-1 more effective as a cancer therapy with potentially fewer off-target effects.

Peptide-based cancer immunotherapy is a rapidly growing field. This study demonstrates that combining an established immunomodulatory peptide with a tumor-targeting peptide can create a more effective hybrid therapeutic. The approach of adding targeting peptides to existing therapeutic peptides could be broadly applicable to improving other peptide drugs.

This was an animal study using mouse tumor models, and human efficacy remains untested. The specific dosing, treatment schedules, and long-term safety were not detailed in the abstract. The hydrocortisone immunosuppression model is a simplified representation of clinical immunosuppression.